Other
Senior Director, Biostatistics
Braveheart Bio
Greenhouse
- Location
- San Francisco, CA or Remote or Hybrid, Not specified
- Type
- Not specified
- Salary
- Salary not specified
- Posted
- 19 Nov 2026
About us: Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The role: The Senior Director, Biostatistics, is a hands-on program-level statistical leader for our lead cardiovascular program, reporting to the VP, Head of Biometrics. The Senior Director serves as the program statistical lead for BHB-1893, owning the statistical strategy, design, analysis, and interpretation of late-sta
About us: Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The role: The Senior Director, Biostatistics, is a hands-on program-level statistical leader for our lead cardiovascular program, reporting to the VP, Head of Biometrics. The Senior Director serves as the program statistical lead for BHB-1893, owning the statistical strategy, design, analysis, and interpretation of late-stage Phase 2 and Phase 3 studies while doing much of the statistical work directly. The Senior Director manages CRO and vendor biostatistics and statistical programming work, collaborates closely with external partners, represents biostatistics on program teams and in health authority interactions, and drives the statistical components of regulatory filings. The ideal candidate brings deep late-stage and regulatory expertise, sound scientific judgment, and a strong preference for hands-on work in a lean, fast-moving biotech environment. This role is a key partner to Clinical Development, Clinical Operations, Data Management, Regulatory, Safety, Medical Affairs, and Clinical Pharmacology, and contributes to building the processes and standards of a growing late-stage organization. Key responsibilities: Serve as program statistical lead for BHB-1893, setting and executing the statistical strategy for Phase 2 and Phase 3 development across oHCM and nHCM, in alignment with the VP, Head of Biometrics Provide statistical leadership on study design, including endpoint selection, sample size and power, randomization, estimands (ICH E9(R1)), multiplicity control, and adaptive or innovative designs where appropriate Personally author statistical sections of protocols, statistical analysis plans (SAPs), DMC charters, randomization specifications, and TFL shells Manage CRO and external biostatistics and statistical programming vendors day to day, including vendor selection, scopes of work, budgets, change orders, timelines, and quality of deliverables; hold vendors accountable and escalate issues as needed Collaborate with external partners, including co-development or licensing partners, academic collaborators, steering committees, independent DMC statisticians, and key opinion leaders, to align on statistical strategy, analyses, and data sharing Serve as statistical lead in interactions with FDA, EMA, and other health authorities, including End-of-Phase 2, Type B/C, and Scientific Advice meetings, and responses to agency questions Lead statistical contributions to regulatory submissions (NDA/MAA), including integrated summaries of safety and efficacy (ISS/ISE), clinical study reports, and Module 2 summaries Partner with Data Management and Statistical Programming on interim analyses, DMC data cuts, unblinding procedures and firewalls, database locks, and delivery of CDISC-compliant (SDTM/ADaM) datasets Interpret and communicate study results to executive leadership, the Board, investigators, and external partners; support topline readouts, publications, and scientific presentations Collaborate with Clinical Pharmacology and Translational Science on exposure–response, PK/PD, biomarker, and model-informed drug development analyses Support medical affairs, real-world evidence, and health economics analyses, including exploratory and post-hoc analyses Perform hands-on simulations, sample size and power calculations, and probability-of-success analyses to support study design and program decisions Contribute to biostatistics SOPs, work instructions, templates, and standards, ensuring inspection readiness and compliance with GCP, ICH E9, and regulatory requirements Perform independent statistical analyses and quality review of CRO outputs using SAS and/or R Required experience & skills: MS or PhD in Biostatistics, Statistics, or a closely related quantitative field At least 12 years of biostatistics experience with a PhD, or at least 15 years with an MS, within the biotechnology, pharmaceutical, or CRO industry Direct experience as lead statistician on late-stage Phase 2 and Phase 3 programs, including dose-ranging and pivotal trials, from design through database lock, analysis, and reporting Hands-on regulatory filing experience is required, having led or served as a senior statistician on at least one NDA, BLA, or MAA submission, including ISS/ISE, CDISC submission datasets, and responses to health authority questions Deep expertise in clinical trial design, estimands, multiplicity, missing data methods, interim analyses, and group sequential and adaptive designs Proven experience managing CROs and statistical vendors, with a track record of driving accountability, quality, and on-time delivery Experience collaborating effectively with external partners, such as co-development or licensing partners, academic groups, and independent DMCs Strong hands-on statistical skills, with the ability to independently perform analyses, simulations, and review of programming outputs; people management experience is not required Working knowledge of SAS and/or R, CDISC standards (SDTM, ADaM), GCP, ICH E9/E9(R1), and relevant FDA and EMA guidance Ability to communicate complex statistical concepts clearly to non-statisticians, including executives, the Board, investigators, and regulators Demonstrated ability to work cross-functionally in a lean, fast-paced development environment Strong written and verbal communication skills with a collaborative, team-oriented approach Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude Preferred experience & skills: Experience in cardiovascular clinical development, ideally including HCM or heart failure, and familiarity with endpoints such as peak VO2, KCCQ, NYHA class, and echocardiographic measures (e.g., LVOT gradient) Experience supporting multiple regulatory filings and taking a product through approval and launch Prior experience as program statistical lead in a small or mid-sized biotech transitioning into late-stage development Experience preparing for or presenting at FDA Advisory Committee meetings Experience with independent DMC/DSMB interactions and statistical reporting Base Salary Range: $280,000 - $320,000 This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering. We are an equal opportunity employer. We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law. Braveheart participates in the federal E ‑ Verify program to confirm employment authorization for all new hires. To learn more about E-Verify please review this poster .